Claims for Patent: 5,635,600

Summary for Patent: 5,635,600

Title:	Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes
Abstract:	Monoclonal antibodies which react specifically to Fc receptor of human effector cells IgG are disclosed. Binding of the antibodies to the receptor is not blocked by human immunoglobulin G. The antibodies are useful for targeting human effector cells (e.g. macrophages) against a target cell (e.g. a cancer cell, an infectious agent, etc.) For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can be used to kill target cells by cell mediated antibody dependent cytolysis.
Inventor(s):	Fanger; Michael W. (Lebanon, NH), Guyre; Paul M. (Hanover, NH), Anderson; Clark L. (Columbus, OH)
Assignee:	Trustees of Dartmouth College (Hanover, NH)
Application Number:	08/364,435
Patent Claims:	1. A bifunctional antibody or heteroantibody, comprising: a. at least one antigen binding region derived from an antibody, which binds specifically to the human 72 kDa high affinity Fc receptor for IqG on monocytes, binding not being blocked by human immunoglobulin G; and b. at least one antigen binding region specific for a target epitope. 2. A bifunctional antibody or heteroantibody of claim 1, wherein the anti-Fc receptor antibody is mab 32.2, produced by hybridoma cell line ATCC No. HB9469 or subclones thereof. 3. A bifunctional antibody or heteroantibody of claim 1, wherein the target epitope is an epitope of a cancer cell. 4. A bifunctional antibody or heteroantibody of claim 1, wherein the target epitope is an epitope of an infectious agent. 5. A bifunctional antibody or heteroantibody, comprising: a. an antigen binding region derived from an antibody which i. binds specifically to an epitope of the 72 kDa high affinity Fc receptor for IgG on human monocytes, the epitope being distinct from the ligand binding site for Fc of the receptor; ii. is capable of binding to IgG-occupied Fc receptor; and iii. is not blocked from binding to the receptor by human IgG; and b. an antigen binding region derived from an antibody specific for an epitope of a target cell. 6. A bifunctional antibody or heteroantibody of claim 5, wherein the anti-Fc receptor antibody is mab 32.2, produced by hybridoma cell line ATCC No. HB9469 or subclones thereof. 7. A bifunctional antibody or heteroantibody of claim 5, wherein the target cell is selected from the group consisting of a cancer cell, an infectious agent, an IgE-producing cell and an autoimmune cell. 8. A heteroantibody, comprising: a. an antibody or antibody binding fragment specific for 72 kDa high affinity Fc receptor for IgG on human monocytes, the binding of which to the human Fc receptor is not blocked by human immunoglobulin G; b. an antibody or antibody binding fragment thereof specific for an epitope of a target cell. 9. A heteroantibody of claim 8, wherein the anti-Fc receptor antibody is mab 32.2 produced by hybridoma cell line ATCC No. HB9469 or subclones thereof. 10. A heteroantibody of claim 8, wherein the target cell is selected from the group consisting of a cancer cell, an infectious agent, an IgE-producing cell and an autoimmune cell. 11. A bifunctional antibody or heteroantibody comprising: a. at least one antigen binding region derived from mab 32.2 produced by hybridoma cell line ATCC No. HB9469 or subclones thereof; and b. at least one antigen binding region derived from an antibody specific for an epitope of a target cell. 12. A bifunctional antibody or heteroantibody of claim 11, wherein the target cell is a cancer cell. 13. A heteroantibody of claim 8, which comprises chemically crosslinked Fab fragments. 14. A heteroantibody of claim 8, which comprises chemically crosslinked whole antibodies. 15. A heteroantibody, comprising: a. an Fab fragment which binds specifically to the human 72 kDa high affinity Fc receptor for IgG on monocytes, the antibody binding site on the receptor being distinct from the ligand binding site for Fc and binding not being blocked by human immunoglobulin G; and b. an Fab fragment which binds an epitope of a target cell. 16. A heteroantibody of claim 15, wherein the Fab fragments are chemically crosslinked. 17. A heteroantibody of claim 15, wherein the target cell is selected from the group consisting of a cancer cell, an infectious agent, an IgE-producing cell and an autoimmune cell. 18. The bifunctional antibody or heteroantibody of claim 3, wherein the cancer cell is selected from the group consisting of myeloid leukemia, small cell carcinoma of the lung, ovarian carcinoma and colon carcinoma. 19. The bifunctional antibody or heteroantibody of claim 3, wherein the cancer cell is an ovarian carcinoma. 20. The bifunctional antibody or heteroantibody of claim 19, wherein the antigen-binding regions are chemically crosslinked. 21. The bifunctional antibody or heteroantibody of claim 20, wherein the antigen binding regions are Fab fragments. 22. The bifunctional antibody or heteroantibody of claim 5, wherein the target cell is selected from the group consisting of myeloid leukemia, small cell carcinoma of the lung, ovarian carcinoma and colon carcinoma. 23. The bifunctional antibody or heteroantibody of claim 5, wherein the target cell is an ovarian carcinoma cell. 24. The bifunctional antibody or heteroantibody of claim 23, wherein the antigen binding regions are chemically crosslinked. 25. The bifunctional antibody or heteroantibody of claim 24, wherein the antigen binding regions are Fab fragments. 26. The heteroantibody of claim 8, wherein the target cell is selected from the group consisting of myeloid leukemia, small cell carcinoma of the lung, ovarian carcinoma and colon carcinoma. 27. The heteroantibody of claim 8, wherein the target cell is an ovarian carcinoma cell. 28. The heteroantibody of claim 27, wherein the antigen binding regions are chemically crosslinked.

Details for Patent 5,635,600

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Csl Behring Ag	CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN	immune globulin intravenous (human)	For Injection	102367	07/27/2000		2014-06-03
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	07/26/2007		2014-06-03
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	10/02/2009		2014-06-03